MedTrace Logo

Aldosterone in Diabetic Nephropathy

NCT00870402 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2009-03-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

Spironolactone

25 mg per day for 9 months

DRUG

Placebo

Placebo 1 tablet per day for nine months

Sponsors & Collaborators

  • Universidad de los Andes, Chile

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2009-12-31
Completion
2010-03-31

Countries

  • Chile

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00870402 on ClinicalTrials.gov